A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Manuela Tiako Meyo; Jeanne Chen; Francois Goldwasser; Laure Hirsch; Olivier Huillard

doi:10.2147/TCRM.S263832

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Ther Clin Risk Manag. 2022 Jul 8:18:683-698. doi: 10.2147/TCRM.S263832. eCollection 2022.

Authors

Manuela Tiako Meyo^{1

2}, Jeanne Chen^{1

2}, Francois Goldwasser^{1

2}, Laure Hirsch^{1

2}, Olivier Huillard^{1

2}

Affiliations

¹ Department of Medical Oncology, Institut du Cancer Paris CARPEM, AP-HP, APHP.Centre, Hôpital Cochin, Paris, France.
² Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), AP-HP, APHP.Centre, Hôpital Cochin, Paris, France.

Abstract

Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent of immune checkpoint inhibitors (ICI) or VEGFR TKI plus ICI combinations. This article focuses on the profile of one of these ICI plus VEGFR TKI combination, avelumab plus axitinib. We detail the characteristics of each drug separately, and then we explore the rationale for their association, its efficacy and the resulting toxicity. Finally, we examine the factors associated with avelumab plus axitinib outcomes, and their impact on therapeutic strategy.

Keywords: avelumab; axitinib; immune checkpoint inhibitor; pharmacology; renal cell carcinoma; vascular endothelial growth factor.

Publication types

Review